Chronic obstructive pulmonary disease exacerbation episodes derived from electronic health record data validated using clinical trial data

被引:10
作者
Sperrin, Matthew [1 ]
Webb, David J. [2 ]
Patel, Pinal [3 ]
Davis, Kourtney J. [4 ]
Collier, Susan [5 ]
Pate, Alexander [1 ]
Leather, David A. [5 ]
Pimenta, Jeanne M. [6 ]
机构
[1] Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Manchester, Lancs, England
[2] GlaxoSmithKline Plc, Real World Data & Analyt, Harlow, Essex, England
[3] GlaxoSmithKline Plc, Clin Stat Resp, Uxbridge, Middx, England
[4] GlaxoSmithKline Plc, Real World Data & Analyt, Collegeville, PA USA
[5] GlaxoSmithKline Plc, Resp Therapy Area Unit, Brentford, England
[6] GlaxoSmithKline Plc, Epidemiol, Global Med, Stockley Pk West,1-3 Ironbridge Rd, Uxbridge UB11 1BT, Middx, England
关键词
algorithms; chronic obstructive; electronic health records; pharmacoepidemiology; pulmonary disease; validation; SERIES PRAGMATIC TRIALS; EHR DATA; COPD;
D O I
10.1002/pds.4883
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose To validate an algorithm for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) episodes derived in an electronic health record (EHR) database, against AECOPD episodes collected in a randomized clinical trial using an electronic case report form (eCRF). Methods We analyzed two data sources from the Salford Lung Study in COPD: trial eCRF and the Salford Integrated Record, a linked primary-secondary routine care EHR database of all patients in Salford. For trial participants, AECOPD episodes reported in eCRF were compared with algorithmically derived moderate/severe AECOPD episodes identified in EHR. Episode characteristics (frequency, duration), sensitivity, and positive predictive value (PPV) were calculated. A match between eCRF and EHR episodes was defined as at least 1-day overlap. Results In the primary effectiveness analysis population (n = 2269), 3791 EHR episodes (mean [SD] length: 15.1 [3.59] days; range: 14-54) and 4403 moderate/severe AECOPD eCRF episodes (mean length: 13.8 [16.20] days; range: 1-372) were identified. eCRF episodes exceeding 28 days were usually broken up into shorter episodes in the EHR. Sensitivity was 63.6% and PPV 71.1%, where concordance was defined as at least 1-day overlap. Conclusions The EHR algorithm performance was acceptable, indicating that EHR-derived AECOPD episodes may provide an efficient, valid method of data collection. Comparing EHR-derived AECOPD episodes with those collected by eCRF resulted in slightly fewer episodes, and eCRF episodes of extreme lengths were poorly captured in EHR. Analysis of routinely collected EHR data may be reasonable when relative, rather than absolute, rates of AECOPD are relevant for stakeholders' decision making.
引用
收藏
页码:1369 / 1376
页数:8
相关论文
共 20 条
[1]   Time course and pattern of COPD exacerbation onset [J].
Aaron, Shawn D. ;
Donaldson, Gavin C. ;
Whitmore, George A. ;
Hurst, John R. ;
Ramsay, Tim ;
Wedzicha, Jadwiga A. .
THORAX, 2012, 67 (03) :238-243
[2]   STATISTICS NOTES - DIAGNOSTIC-TESTS-1 - SENSITIVITY AND SPECIFICITY .3. [J].
ALTMAN, DG ;
BLAND, JM .
BRITISH MEDICAL JOURNAL, 1994, 308 (6943) :1552-1552
[3]   How is the electronic health record being used? Use of EHR data to assess physician-level variability in technology use [J].
Ancker, Jessica S. ;
Kern, Lisa M. ;
Edwards, Alison ;
Nosal, Sarah ;
Stein, Daniel M. ;
Hauser, Diane ;
Kaushal, Rainu .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2014, 21 (06) :1001-1008
[4]  
[Anonymous], SALF INT REC SHAR PA
[5]   Using Electronic Health Records for Population Health Research: A Review of Methods and Applications [J].
Casey, Joan A. ;
Schwartz, Brian S. ;
Stewart, Walter F. ;
Adler, Nancy E. .
ANNUAL REVIEW OF PUBLIC HEALTH, VOL 37, 2016, 37 :61-81
[6]   Trustworthy reuse of health data: A transnational perspective [J].
Geissbuhler, A. ;
Safran, C. ;
Buchan, I. ;
Bellazzi, R. ;
Labkoff, S. ;
Eilenberg, K. ;
Leese, A. ;
Richardson, C. ;
Mantas, J. ;
Murray, P. ;
De Moor, G. .
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2013, 82 (01) :1-9
[7]   Multidimensional Evidence Generation and FDA Regulatory Decision Making Defining and Using "Real-World" Data [J].
Jarow, Jonathan P. ;
LaVange, Lisa ;
Woodcock, Janet .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (08) :703-704
[8]   Series: Pragmatic trials and real world evidence: Paper 8. Data collection and management [J].
Meinecke, Anna-Katharina ;
Welsing, Paco ;
Kafatos, George ;
Burke, Des ;
Trelle, Sven ;
Kubin, Maria ;
Nachbaur, Gaelle ;
Egger, Matthias ;
Zuidgeest, Mira .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2017, 91 :13-22
[9]   Putting patients in control of data from electronic health records [J].
New, John P. ;
Leather, David ;
Bakerly, Nawar Diar ;
McCrae, John ;
Gibson, J. Martin .
BMJ-BRITISH MEDICAL JOURNAL, 2018, 360 :j5554
[10]   Obtaining real-world evidence: the Salford Lung Study [J].
New, John P. ;
Bakerly, Nawar Diar ;
Leather, David ;
Woodcock, Ashley .
THORAX, 2014, 69 (12) :1152-1154